Kanabo Group PLC Admission and Total Voting Rights (3002H)
26 Julho 2023 - 10:00AM
UK Regulatory
TIDMKNB
RNS Number : 3002H
Kanabo Group PLC
26 July 2023
26 July 2023
Kanabo Group PLC
("Kanabo" or the "Company")
Admission and Total Voting Rights
The Company announces today, 26 July 2023, 18,749,999 number of
ordinary shares were admitted to trading on the Standard List of
the London Stock Exchange ("Admission")
Following Admission, for the purposes of the Financial Conduct
Authority's Disclosure Guidance and Transparency Rules, Kanabo
announces that the Company has 630,427,870 ordinary shares of 2.5p
each in issue ("Ordinary Shares"), each share carrying the right to
one vote. The figure of 630,427,870 should be used by shareholders
in the Company as the denominator for the calculations by which
they will determine if they are required to notify their interest
in, or a change to their interest in, the Company under the
Financial Conduct Authority's Disclosure Guidance and Transparency
Rules.
The Directors of the Company accept responsibility for the
contents of this announcement.
For further information, please visit
http://www.kanabogroup.com/ or contact the following:
Enquiries:
Kanabo Group plc via Vigo Consulting
Avihu Tamir, Chief Executive Officer +44 (0)20 7390 0230
Assaf Vardimon, Chief Financial Officer
Ian Mattioli, Non-Executive Chair of the
Board
Peterhouse Capital Ltd (Financial Adviser
and Broker)
Eran Zucker/ Lucy Williams / Charles Goodfellow +44 (0)20 7469 0930
Vigo Consulting (Financial Public Relations/Investor
Relations)
Jeremy Garcia / Fiona Hetherington / Verity
Snow +44 (0)20 7390
kanabo@vigoconsulting.com 0230
About Kanabo Group Plc
Kanabo Group Plc (LSE:KNB) is a healthtech company committed to
revolutionising patient care through its innovative technology
platform and disruptive product offerings. Since its inception in
2017, Kanabo has been focused on researching, developing, and
commercialising regulated medicinal cannabis-derived formulations
and therapeutic inhalation devices.
Kanabo's NHS-approved online telehealth platform, The GP
Service, provides patients with video consultations, online
prescriptions, and primary care services. The Company is a leader
in its field, focusing on improving patient outcomes and providing
more accessible healthcare experiences.
The Company's partially owned subsidiary, Kanabo Agritec Ltd, is
a cultivation consultancy supporting cannabis businesses in
developing new farms through infrastructural, research, and product
guidance. These farms deliver high-quality raw materials for
Kanabo's formulas and product line.
In March 2023, Kanabo successfully launched its Pain Clinic,
Treat It, under the expert guidance of its technological and
product expertise. Treat It initially focuses on chronic pain
management using plant-based medicine and treatments that are
currently unavailable through traditional channels.
At Kanabo Group Plc, we are dedicated to providing patients with
the highest quality medical treatments and more accessible
healthcare experiences.
Visit www.kanabogroup.com for more information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEEAAXKASEDEFA
(END) Dow Jones Newswires
July 26, 2023 09:00 ET (13:00 GMT)
Kanabo (LSE:KNB)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Kanabo (LSE:KNB)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
